Growth Hormone Deficiency Clinical Trial
Official title:
A Randomized, Multicenter, 3 Month Phase IV Study to Evaluate the Effect on Subject Adherence With Injection Schedule by Using the Easypod™ rhGH Delivery Device
Verified date | April 2015 |
Source | EMD Serono |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This study will help to determine whether an injection log on a recombinant human growth hormone (rhGH) delivery device improves subjects' adherence with injection schedules. Adherence will be compared between a group of subjects who are aware of the injection log on the easypod™ rhGH delivery device and a group of subjects who are not aware of the easypod™ injection log. It is the study hypothesis that subject non-adherence rate is different for those who are aware of the injection log capability versus those who are unaware of the injection log capability. Subject perception will also be evaluated by comparing the ease and convenience of use and subject preference for the easypod™ compared to two other rhGH pen injection devices.
Status | Completed |
Enrollment | 42 |
Est. completion date | October 2009 |
Est. primary completion date | May 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 10 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Be male or female from 10 to 18 years of age, inclusive, with open epiphyses - Have GH deficiency diagnosed by treating pediatric endocrinologist for at least 6 months - Be undergoing rhGH treatment via self-injection using the Lilly Humatrope® or Pfizer Genotropin® pen injection device for at least 6 months - Be willing and able to comply with the protocol for the duration of the trial - Have access to the Internet - Be able to read, speak and understand English - If female of childbearing potential, have a negative urine pregnancy test at Screening and use an acceptable form of birth control during the trial, including abstinence, a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide Exclusion Criteria: - Known allergy or hypersensitivity to rhGH or prescribed diluent (0.3% metacresol for click.easy® cartridge) - Severe illness during the previous 6 months - Active malignancy (except non-melanomatous skin malignancies) - Diabetes mellitus (type I or II) - Pregnancy or lactation - Any medical condition that, in the opinion of the Investigator, would jeopardize the subject's safety following exposure to the investigational device - Participation in any other investigational study during the duration of participation in this trial |
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)
Country | Name | City | State |
---|---|---|---|
United States | US Medical Information | Rockland | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
EMD Serono |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent rhGH Injections Missed During the Treatment Period (Based on the Easypod™ Injection Log) | 90 Days | No | |
Secondary | Subjects Perception of Easypod Ease of Use Compared to Two Other rhGH Pen Injection Devices | 90 Days | No | |
Secondary | Subject Perceptions of Easypod: Storage Convenience Compared to Two Other rhGH Pen Injection Devices. | 90 Days | No | |
Secondary | Subject Perceptions of Easypod: Preference to Use Easypod Over Two Other rhGH Pen Injection Devices. | 90 Days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243852 -
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
|
N/A | |
Completed |
NCT01440686 -
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00990340 -
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
|
Phase 4 | |
Completed |
NCT00149708 -
Consequence of Lifetime Isolated Growth Hormone Deficiency
|
N/A | |
Completed |
NCT00235599 -
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
|
N/A | |
Completed |
NCT00459940 -
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
N/A | |
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00004365 -
Study of Pituitary Size and Function in Familial Dwarfism of Sindh
|
N/A | |
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT04121780 -
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Phase 2 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT01090778 -
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
|
Phase 2 | |
Completed |
NCT01062529 -
Peripheral Metabolic Effects of Somatostatin
|
N/A | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00616278 -
National Cooperative Growth Study in CKD
|
N/A | |
Completed |
NCT02693522 -
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02908958 -
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
|
Phase 4 | |
Terminated |
NCT01243892 -
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
|
N/A | |
Withdrawn |
NCT00638287 -
Inter-Assay Growth Hormone and IGF-I Variability
|
N/A | |
Completed |
NCT00957671 -
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
|
Phase 4 |